AT(N) Biomarker profiles and Alzheimer’s Disease clinical status and memory in adults with down syndrome

Background Down syndrome (DS) is seen as a genetic form of Alzheimer’s disease (AD). The National Institute on Aging and the Alzheimer’s Association proposed the AT(N) model for classifying AD biomarkers of amyloid (A), tau (T), and neurodegeneration or neuronal injury ([N]) in non‐DS populations. I...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's & dementia 2023-06, Vol.19 (S3), p.n/a
Hauptverfasser: Hartley, Sigan L, Tudorascu, Dana L., Lee, Laise, Petersen, Melissa, Cohen, Ann D., Klunk, William E, Laymon, Charles M, Zaman, Shahid, Christian, Bradley T., Handen, Benjamin L.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue S3
container_start_page
container_title Alzheimer's & dementia
container_volume 19
creator Hartley, Sigan L
Tudorascu, Dana L.
Lee, Laise
Petersen, Melissa
Cohen, Ann D.
Klunk, William E
Laymon, Charles M
Zaman, Shahid
Christian, Bradley T.
Handen, Benjamin L.
description Background Down syndrome (DS) is seen as a genetic form of Alzheimer’s disease (AD). The National Institute on Aging and the Alzheimer’s Association proposed the AT(N) model for classifying AD biomarkers of amyloid (A), tau (T), and neurodegeneration or neuronal injury ([N]) in non‐DS populations. It is not yet known how the AT(N) classification system maps onto AD pathology and symptomology in DS. The goals of the present study were to: 1) examine AT(N) profiles in DS based on PET amyloid‐beta (Aβ) (A), tau PET (T), and hippocampal volume ([N]); and 2) evaluate potential differences in clinical AD status and memory performance by AT(N) profile in DS. Method Analyses included 138 adults with DS (age: M = 39.1, SD = 8.0) enrolled in the Alzheimer’s Biomarker Consortium‐ Down Syndrome study. PET Aβ and tau were assessed using [11C]PiB and [18F]AV‐1451. Structural MRI data was used to index hippocampal volume and adjusted for intracranial volume. Thresholds for elevated (+ vs. ‐) A (Aβ CL >19), T (tau composite SUVr >1.21) and (N) (hippocampal volume < 1 SD from sample mean) were based on prior studies. Clinical AD status (cognitively stable, mild cognitive impairment [MCI‐DS], dementia, and unable to determine) were based on direct measures and caregiver‐report but blind to imaging and biofluid data. The Cued Recall Test was used to assess episodic memory. Result Overall, 66% of participants were A‐/T‐/(N)‐, 14% were A+/T‐/(N)‐, 9% were A+/T+/(N)‐, and 5% were A+/T+/(N)+. The remaining 6% had an alternative profile (e.g. A‐/T‐/(N)+). One‐way analyses of variance indicated a significant difference in age and clinical AD status by A/T/N profile. General linear models controlling for age and premorbid intellectual disability level indicated differences in memory by A/T/(N) profile. Conclusion This study adds to the understanding of AT(N) biomarker profiles in DS and their association with AD symptomology. Clinical AD status of MCI‐DS and dementia and worse memory performance were associated with elevated T and (N), in line with non‐DS populations. The unable to determine status paralleled the MCI and dementia status groups. Findings inform models that predict the transition to AD in DS. aging after age 90.
doi_str_mv 10.1002/alz.062613
format Article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_alz_062613</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ALZ062613</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1133-38258d7093f70d790606a4f15e3bee343991ff92743760b077658e7a1bc70d813</originalsourceid><addsrcrecordid>eNp9kL1OwzAUhS0EEqWw8AQeASnlOo7jZAwtf1IFS1lYIje5Vl2cpLJTVenEa_B6PAlBqRiZzhm-e6XzEXLJYMIAwltl9xOIw5jxIzJiQoSBCGV6_NdjOCVn3q8BIkiYGJF1trh6uaZ3pqmU-0BHN67RxqKnqi5pZvcrNBW6788vT2fGo_JIC2tqUyhLfava7UBWWDWuo6amqtza1tOdaVe0bHY19V1duqbCc3KilfV4ccgxeXu4X0yfgvnr4_M0mwcFY5wHPAlFUkpIuZZQyhRiiFWkmUC-ROQRT1OmdRrKiMsYliBlLBKUii2Lnk8YH5Ob4W_hGu8d6nzjTL-uyxnkv5by3lI-WOphNsC7fnT3D5ln8_fDzQ8l3mpD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>AT(N) Biomarker profiles and Alzheimer’s Disease clinical status and memory in adults with down syndrome</title><source>Access via Wiley Online Library</source><creator>Hartley, Sigan L ; Tudorascu, Dana L. ; Lee, Laise ; Petersen, Melissa ; Cohen, Ann D. ; Klunk, William E ; Laymon, Charles M ; Zaman, Shahid ; Christian, Bradley T. ; Handen, Benjamin L.</creator><creatorcontrib>Hartley, Sigan L ; Tudorascu, Dana L. ; Lee, Laise ; Petersen, Melissa ; Cohen, Ann D. ; Klunk, William E ; Laymon, Charles M ; Zaman, Shahid ; Christian, Bradley T. ; Handen, Benjamin L.</creatorcontrib><description>Background Down syndrome (DS) is seen as a genetic form of Alzheimer’s disease (AD). The National Institute on Aging and the Alzheimer’s Association proposed the AT(N) model for classifying AD biomarkers of amyloid (A), tau (T), and neurodegeneration or neuronal injury ([N]) in non‐DS populations. It is not yet known how the AT(N) classification system maps onto AD pathology and symptomology in DS. The goals of the present study were to: 1) examine AT(N) profiles in DS based on PET amyloid‐beta (Aβ) (A), tau PET (T), and hippocampal volume ([N]); and 2) evaluate potential differences in clinical AD status and memory performance by AT(N) profile in DS. Method Analyses included 138 adults with DS (age: M = 39.1, SD = 8.0) enrolled in the Alzheimer’s Biomarker Consortium‐ Down Syndrome study. PET Aβ and tau were assessed using [11C]PiB and [18F]AV‐1451. Structural MRI data was used to index hippocampal volume and adjusted for intracranial volume. Thresholds for elevated (+ vs. ‐) A (Aβ CL &gt;19), T (tau composite SUVr &gt;1.21) and (N) (hippocampal volume &lt; 1 SD from sample mean) were based on prior studies. Clinical AD status (cognitively stable, mild cognitive impairment [MCI‐DS], dementia, and unable to determine) were based on direct measures and caregiver‐report but blind to imaging and biofluid data. The Cued Recall Test was used to assess episodic memory. Result Overall, 66% of participants were A‐/T‐/(N)‐, 14% were A+/T‐/(N)‐, 9% were A+/T+/(N)‐, and 5% were A+/T+/(N)+. The remaining 6% had an alternative profile (e.g. A‐/T‐/(N)+). One‐way analyses of variance indicated a significant difference in age and clinical AD status by A/T/N profile. General linear models controlling for age and premorbid intellectual disability level indicated differences in memory by A/T/(N) profile. Conclusion This study adds to the understanding of AT(N) biomarker profiles in DS and their association with AD symptomology. Clinical AD status of MCI‐DS and dementia and worse memory performance were associated with elevated T and (N), in line with non‐DS populations. The unable to determine status paralleled the MCI and dementia status groups. Findings inform models that predict the transition to AD in DS. aging after age 90.</description><identifier>ISSN: 1552-5260</identifier><identifier>EISSN: 1552-5279</identifier><identifier>DOI: 10.1002/alz.062613</identifier><language>eng</language><ispartof>Alzheimer's &amp; dementia, 2023-06, Vol.19 (S3), p.n/a</ispartof><rights>2023 the Alzheimer's Association.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Falz.062613$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Falz.062613$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids></links><search><creatorcontrib>Hartley, Sigan L</creatorcontrib><creatorcontrib>Tudorascu, Dana L.</creatorcontrib><creatorcontrib>Lee, Laise</creatorcontrib><creatorcontrib>Petersen, Melissa</creatorcontrib><creatorcontrib>Cohen, Ann D.</creatorcontrib><creatorcontrib>Klunk, William E</creatorcontrib><creatorcontrib>Laymon, Charles M</creatorcontrib><creatorcontrib>Zaman, Shahid</creatorcontrib><creatorcontrib>Christian, Bradley T.</creatorcontrib><creatorcontrib>Handen, Benjamin L.</creatorcontrib><title>AT(N) Biomarker profiles and Alzheimer’s Disease clinical status and memory in adults with down syndrome</title><title>Alzheimer's &amp; dementia</title><description>Background Down syndrome (DS) is seen as a genetic form of Alzheimer’s disease (AD). The National Institute on Aging and the Alzheimer’s Association proposed the AT(N) model for classifying AD biomarkers of amyloid (A), tau (T), and neurodegeneration or neuronal injury ([N]) in non‐DS populations. It is not yet known how the AT(N) classification system maps onto AD pathology and symptomology in DS. The goals of the present study were to: 1) examine AT(N) profiles in DS based on PET amyloid‐beta (Aβ) (A), tau PET (T), and hippocampal volume ([N]); and 2) evaluate potential differences in clinical AD status and memory performance by AT(N) profile in DS. Method Analyses included 138 adults with DS (age: M = 39.1, SD = 8.0) enrolled in the Alzheimer’s Biomarker Consortium‐ Down Syndrome study. PET Aβ and tau were assessed using [11C]PiB and [18F]AV‐1451. Structural MRI data was used to index hippocampal volume and adjusted for intracranial volume. Thresholds for elevated (+ vs. ‐) A (Aβ CL &gt;19), T (tau composite SUVr &gt;1.21) and (N) (hippocampal volume &lt; 1 SD from sample mean) were based on prior studies. Clinical AD status (cognitively stable, mild cognitive impairment [MCI‐DS], dementia, and unable to determine) were based on direct measures and caregiver‐report but blind to imaging and biofluid data. The Cued Recall Test was used to assess episodic memory. Result Overall, 66% of participants were A‐/T‐/(N)‐, 14% were A+/T‐/(N)‐, 9% were A+/T+/(N)‐, and 5% were A+/T+/(N)+. The remaining 6% had an alternative profile (e.g. A‐/T‐/(N)+). One‐way analyses of variance indicated a significant difference in age and clinical AD status by A/T/N profile. General linear models controlling for age and premorbid intellectual disability level indicated differences in memory by A/T/(N) profile. Conclusion This study adds to the understanding of AT(N) biomarker profiles in DS and their association with AD symptomology. Clinical AD status of MCI‐DS and dementia and worse memory performance were associated with elevated T and (N), in line with non‐DS populations. The unable to determine status paralleled the MCI and dementia status groups. Findings inform models that predict the transition to AD in DS. aging after age 90.</description><issn>1552-5260</issn><issn>1552-5279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kL1OwzAUhS0EEqWw8AQeASnlOo7jZAwtf1IFS1lYIje5Vl2cpLJTVenEa_B6PAlBqRiZzhm-e6XzEXLJYMIAwltl9xOIw5jxIzJiQoSBCGV6_NdjOCVn3q8BIkiYGJF1trh6uaZ3pqmU-0BHN67RxqKnqi5pZvcrNBW6788vT2fGo_JIC2tqUyhLfava7UBWWDWuo6amqtza1tOdaVe0bHY19V1duqbCc3KilfV4ccgxeXu4X0yfgvnr4_M0mwcFY5wHPAlFUkpIuZZQyhRiiFWkmUC-ROQRT1OmdRrKiMsYliBlLBKUii2Lnk8YH5Ob4W_hGu8d6nzjTL-uyxnkv5by3lI-WOphNsC7fnT3D5ln8_fDzQ8l3mpD</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Hartley, Sigan L</creator><creator>Tudorascu, Dana L.</creator><creator>Lee, Laise</creator><creator>Petersen, Melissa</creator><creator>Cohen, Ann D.</creator><creator>Klunk, William E</creator><creator>Laymon, Charles M</creator><creator>Zaman, Shahid</creator><creator>Christian, Bradley T.</creator><creator>Handen, Benjamin L.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202306</creationdate><title>AT(N) Biomarker profiles and Alzheimer’s Disease clinical status and memory in adults with down syndrome</title><author>Hartley, Sigan L ; Tudorascu, Dana L. ; Lee, Laise ; Petersen, Melissa ; Cohen, Ann D. ; Klunk, William E ; Laymon, Charles M ; Zaman, Shahid ; Christian, Bradley T. ; Handen, Benjamin L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1133-38258d7093f70d790606a4f15e3bee343991ff92743760b077658e7a1bc70d813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hartley, Sigan L</creatorcontrib><creatorcontrib>Tudorascu, Dana L.</creatorcontrib><creatorcontrib>Lee, Laise</creatorcontrib><creatorcontrib>Petersen, Melissa</creatorcontrib><creatorcontrib>Cohen, Ann D.</creatorcontrib><creatorcontrib>Klunk, William E</creatorcontrib><creatorcontrib>Laymon, Charles M</creatorcontrib><creatorcontrib>Zaman, Shahid</creatorcontrib><creatorcontrib>Christian, Bradley T.</creatorcontrib><creatorcontrib>Handen, Benjamin L.</creatorcontrib><collection>CrossRef</collection><jtitle>Alzheimer's &amp; dementia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hartley, Sigan L</au><au>Tudorascu, Dana L.</au><au>Lee, Laise</au><au>Petersen, Melissa</au><au>Cohen, Ann D.</au><au>Klunk, William E</au><au>Laymon, Charles M</au><au>Zaman, Shahid</au><au>Christian, Bradley T.</au><au>Handen, Benjamin L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AT(N) Biomarker profiles and Alzheimer’s Disease clinical status and memory in adults with down syndrome</atitle><jtitle>Alzheimer's &amp; dementia</jtitle><date>2023-06</date><risdate>2023</risdate><volume>19</volume><issue>S3</issue><epage>n/a</epage><issn>1552-5260</issn><eissn>1552-5279</eissn><abstract>Background Down syndrome (DS) is seen as a genetic form of Alzheimer’s disease (AD). The National Institute on Aging and the Alzheimer’s Association proposed the AT(N) model for classifying AD biomarkers of amyloid (A), tau (T), and neurodegeneration or neuronal injury ([N]) in non‐DS populations. It is not yet known how the AT(N) classification system maps onto AD pathology and symptomology in DS. The goals of the present study were to: 1) examine AT(N) profiles in DS based on PET amyloid‐beta (Aβ) (A), tau PET (T), and hippocampal volume ([N]); and 2) evaluate potential differences in clinical AD status and memory performance by AT(N) profile in DS. Method Analyses included 138 adults with DS (age: M = 39.1, SD = 8.0) enrolled in the Alzheimer’s Biomarker Consortium‐ Down Syndrome study. PET Aβ and tau were assessed using [11C]PiB and [18F]AV‐1451. Structural MRI data was used to index hippocampal volume and adjusted for intracranial volume. Thresholds for elevated (+ vs. ‐) A (Aβ CL &gt;19), T (tau composite SUVr &gt;1.21) and (N) (hippocampal volume &lt; 1 SD from sample mean) were based on prior studies. Clinical AD status (cognitively stable, mild cognitive impairment [MCI‐DS], dementia, and unable to determine) were based on direct measures and caregiver‐report but blind to imaging and biofluid data. The Cued Recall Test was used to assess episodic memory. Result Overall, 66% of participants were A‐/T‐/(N)‐, 14% were A+/T‐/(N)‐, 9% were A+/T+/(N)‐, and 5% were A+/T+/(N)+. The remaining 6% had an alternative profile (e.g. A‐/T‐/(N)+). One‐way analyses of variance indicated a significant difference in age and clinical AD status by A/T/N profile. General linear models controlling for age and premorbid intellectual disability level indicated differences in memory by A/T/(N) profile. Conclusion This study adds to the understanding of AT(N) biomarker profiles in DS and their association with AD symptomology. Clinical AD status of MCI‐DS and dementia and worse memory performance were associated with elevated T and (N), in line with non‐DS populations. The unable to determine status paralleled the MCI and dementia status groups. Findings inform models that predict the transition to AD in DS. aging after age 90.</abstract><doi>10.1002/alz.062613</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1552-5260
ispartof Alzheimer's & dementia, 2023-06, Vol.19 (S3), p.n/a
issn 1552-5260
1552-5279
language eng
recordid cdi_crossref_primary_10_1002_alz_062613
source Access via Wiley Online Library
title AT(N) Biomarker profiles and Alzheimer’s Disease clinical status and memory in adults with down syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T04%3A20%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AT(N)%20Biomarker%20profiles%20and%20Alzheimer%E2%80%99s%20Disease%20clinical%20status%20and%20memory%20in%20adults%20with%20down%20syndrome&rft.jtitle=Alzheimer's%20&%20dementia&rft.au=Hartley,%20Sigan%20L&rft.date=2023-06&rft.volume=19&rft.issue=S3&rft.epage=n/a&rft.issn=1552-5260&rft.eissn=1552-5279&rft_id=info:doi/10.1002/alz.062613&rft_dat=%3Cwiley_cross%3EALZ062613%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true